HRT: Options, Benefits and Risks
Hormone replacement therapy (HRT) is the most effective treatment for menopausal symptoms — and one of the most debated. Decades of research, including a major study that frightened many women and a long reassessment since, have produced a nuanced picture. This guide explains it honestly: what HRT helps, what the risks are, and how the choice is individual. Educational information only, not medical advice, and it deliberately gives no dosing.
The modern consensus: for most healthy women under 60, or within about ten years of menopause, the benefits of HRT for troublesome symptoms outweigh the risks. For women starting later, or with certain risk factors, the balance shifts. This is why the decision is personal and made with a clinician.
What HRT actually is
HRT replaces the hormones the ovaries stop making. The core components:
- Estrogen — the main treatment for hot flushes, night sweats, vaginal symptoms and bone protection.
- Progestogen — added for women who still have a uterus, because estrogen alone thickens the uterine lining and raises the risk of endometrial cancer. The progestogen protects the lining.
- Local (vaginal) estrogen — a low-dose form for urogenital symptoms alone, with minimal systemic absorption.
What it helps
- Vasomotor symptoms — hot flushes and night sweats; the clearest, most reliable benefit.
- Sleep and mood — largely through reducing night sweats and the general burden of symptoms.
- Urogenital symptoms — vaginal dryness, discomfort and bladder symptoms.
- Bone — reduces postmenopausal bone loss and the risk of fracture, though it is not usually the first-line choice for osteoporosis alone.
The risks, honestly
- Breast cancer. Combined estrogen-plus-progestogen HRT is associated with a small increased risk of breast cancer, rising with duration of use. Estrogen-only HRT (for women without a uterus) carries a smaller or, in some analyses, neutral risk. The absolute increase is small but real.
- Blood clots. Oral estrogen slightly raises the risk of venous thromboembolism. Transdermal estrogen (patch or gel) appears to carry a lower clotting risk — an important distinction.
- Stroke. A small increased risk, more relevant with oral estrogen and in older or higher-risk women.
- Endometrial cancer. Estrogen without a progestogen raises this risk substantially in women with a uterus — which is why the progestogen is added.
The routes
- Oral — convenient, but processed through the liver, which is why it affects clotting factors.
- Transdermal — patch or gel; avoids first-pass liver processing, which is why clotting risk appears lower.
- Local vaginal — creams, pessaries or rings; treats urogenital symptoms with little systemic effect.
The timing question
The "timing hypothesis" holds that HRT started soon after menopause tends to have a more favourable risk profile than HRT started many years later — particularly for cardiovascular outcomes. This is one reason the decision, and when you start, is discussed individually rather than from a rule.
Who needs particular caution
A clinician weighs HRT carefully where there is a history of breast cancer, blood clots, stroke, heart disease, or unexplained vaginal bleeding. For some women, non-hormonal options are more appropriate.
HRT is a prescription treatment with real benefits and real risks that depend on your age, timing, medical history and route of administration. Do not start, stop or change it based on this guide — the decision belongs with you and a qualified clinician.
Educational information only — not medical advice. Evidence evolves, and individual risk depends on personal history. Consult a qualified clinician.
← All guides